Compare QUALCOMM, Inc. (QCOM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? QUALCOMM, Inc. trades at $176.3 (market cap $185.94B), while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: QUALCOMM, Inc. is far larger — about 2.2× Regeneron Pharmaceuticals Inc's market cap, and QUALCOMM, Inc. pays the higher dividend (2.11%). Which is the better fit depends on your goals.
| QCOM | REGN | |
|---|---|---|
Market Cap | $185.94B | $83.43B |
Sector | Technology | Health |
52-Week High | $251.10 | $852.03 |
52-Week Low | $124.07 | $555.51 |
Enterprise Value | $192.90B | $78.14B |
Dividend Yield | 2.11% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $176.4, up 4.54% today, with a bullish technical signal from moving averages and oscillators. The company reported revenue of $44.28B in 2025, with a net income margin of 21.01%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $200.56 price target, while news highlights AI and data center growth amid smartphone market challenges.
The outlook for QCOM is cautiously optimistic, driven by AI and data center expansion, but near-term risks include smartphone demand softness and margin pressures. Investment opportunity lies in diversification beyond handsets, though competition from Nvidia and Intel poses a threat. Earnings growth and execution on AI initiatives are key catalysts for upside.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
